Shares of InMed Pharmaceuticals Inc. (OTCMKTS:IMLFF – Get Free Report) fell 3.6% during mid-day trading on Wednesday . The stock traded as low as $4.77 and last traded at $4.79. 20,203 shares traded hands during trading, an increase of 78% from the average session volume of 11,369 shares. The stock had previously closed at $4.97.
InMed Pharmaceuticals Trading Down 3.6 %
The stock has a 50-day moving average price of $3.82 and a 200 day moving average price of $1.50.
InMed Pharmaceuticals Company Profile
InMed Pharmaceuticals Inc, a clinical stage pharmaceutical company, researches and develops cannabinoid-based therapies. The company's lead product is INM-755, a cannabinol topical cream, which is in a second Phase I clinical trials for the treatment of epidermolysis bullosa. The company is also involved in developing INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-405 for the treatment of orofacial pain.
See Also
- Five stocks we like better than InMed Pharmaceuticals
- Special Purpose Acquisition Company (SPAC) What You Need to Know
- Moderna Shares Spike on H5N1 News—What’s Next for Investors?
- How to Know Which Cryptocurrency to Buy: A Guide for Investors
- Nebius Group (NBIS): A Small-Cap Backed by NVIDIA
- Dividend Payout Ratio Calculator
- Natural Gas Demand to Surge: Top 3 Stocks and ETFs to Consider
Receive News & Ratings for InMed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InMed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
